Gynecologic cancer intergroup (GCIG) consensus review for uterine serous carcinoma

International Journal of Gynecological Cancer

Volumn 24, Issue 9, 2014, Pages S83-S89

  Sagae, Satoru ^a   Susumu, Nobuyuki ^b   Viswanathan, Akila N ^c   Aoki, Daisuke ^b   Backes, Floor J ^d   Provencher, Diane M ^e   Vaughan, Michelle ^f   Creutzberg, Carien L ^g   Kurzeder, Christian ^h   Kristensen, Gunnar ⁱ   Lee, Chulmin ^j   Kurtz, Jean Emmanuel ^k   Glasspool, Rosalind M ^l   Small, William ^m  

^a Sapporo General Hospital of Hokkaido Railway Company   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h KLINIKEN ESSEN MITTE   (Germany)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j Inje University College of Medicine   (South Korea)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^m LOYOLA UNIVERSITY CHICAGO   (United States)

more..

Author keywords

GCIG; Review; Uterine serous carcinoma

Indexed keywords

ESTROGEN; PROGESTERONE; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONSENSUS; COPY NUMBER VARIATION; DNA METHYLATION; GENE MUTATION; GENETICS; HUMAN; MEDICAL SOCIETY; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA; CYSTADENOCARCINOMA, SEROUS; FEMALE; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PATHOLOGY; PRACTICE GUIDELINE; UTERINE NEOPLASMS;

COMBINED MODALITY THERAPY; CONSENSUS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UTERINE NEOPLASMS;

EID: 84936082191     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000264     Document Type: Article

References (30)

1. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
2. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93-108.
3. Naumann RW. Uterine papillary serous carcinoma: state of the state. Curr Oncol Rep. 2008;10:505-511.
4. Bokhman JV. Two pathogenic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
5. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95:593-596.
6. Boruta DM, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142-513.
7. Boruta DM 2nd, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer. 2004;101:2214-2221.
8. Lavie O, Hornreich G, Ben-Arie A, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol. 2004;92: 521-524.
9. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260-1267.
10. Yi X, Zheng W. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol. 2008;20:20-25.
11. Huang GS, Gebb JS, Einstein MH, et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol. 2007;196:243.e1-e5.
12. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomized study. Lancet. 2009;373:125-136.
13. Benedetti Pancini P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst. 2008;100:1707-1716.
14. Goff BA, Kato D, Schmidt RK, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54:264-268.
15. Growdon WB, Rauh-Hain AJ, Cordon A, et al. Prognostic determinants in patients with stage I uterine papillary serous carcinoma. A 15-year multi-institutional review. Int J Gyencol Oncol. 2012;22:417-424.
16. Fader AN, Starks D, Rose PG, et al. Percentage USC, lymphovascular invasion, and tumor size are not independent predictors of recurrence. Gynecol Oncol. 2009;112:S72-S74.
17. Rauh-Hain JA, Growdon WB, Schorge JO, et al. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol. 2010;119:299-304.
18. Viswanathan AN, Macklin EA, Berkowitz R, et al. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol. 2011;123:542-547.
19. Fader AN, Drake RD, O'Malley DM, et al. Platinum/taxanebased chemotherapy with or without radiotherapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115:2119-2127.
20. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46:2422-2431.
21. Kelly MG, O'Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (USC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005;98:353-359.
22. Barney BM, Petersen IA, Mariani A, et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys. 2013;85:109-115.
23. Fader AN, Nagel C, Axtell AE, et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improve recurrence and survival outcomes. Gynecol Oncol. 2009;112:558-562.
24. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 2004;22:2159-2166.
25. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-Abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36-44.
26. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2008;22:131-136.
27. Miller DS. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2012;125:771.
28. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100:349-354.
29. Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22:3126-3132.
30. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2011;29:2259-2265.